Clearstead Advisors’s Astria Therapeutics ATXS Stock Holding History

Clearstead Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-101	Closed	-$1.32K	–	2297
2025 Q4	$1.32K	Buy	+101	New	+$1.21K	﹤0.01%	2196
2025 Q3	–	Sell	-416	Closed	-$2.23K	–	3101
2025 Q2	$2.23K	Hold	416	–	–	﹤0.01%	2301
2025 Q1	$2.22K	Hold	416	–	–	﹤0.01%	1883
2024 Q4	$3.72K	Hold	416	–	–	﹤0.01%	1769
2024 Q3	$4.58K	Hold	416	–	–	﹤0.01%	1720
2024 Q2	$3.79K	Buy	+416	New	+$4.06K	﹤0.01%	1732

Clearstead Advisors's ATXS Position: Q1 2026 in Review

Clearstead Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 101 shares — an estimated $1.32K sold.

Clearstead Advisors first reported a position in ATXS in Q2 2024 and held it in 6 quarters. The position peaked at $4.58K in Q3 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Clearstead Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Clearstead Advisors sold 101 Astria Therapeutics shares in Q1 2026, an estimated $1.32K.
Clearstead Advisors first reported a position in Astria Therapeutics in Q2 2024 and held it in 6 quarters.
Clearstead Advisors's Astria Therapeutics position peaked at $4.58K in Q3 2024.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.